



2, rue Maurice Hartmann  
92 130 – Issy-Les-Moulineaux

**Laboratoires NEGMA S.A.S.U.**

Siège social : 1 bis avenue Jean d'Alembert – 78 990 ELANCOURT

Capital Social : € 28.868.371

**Rapport du commissaire aux comptes sur les comptes annuels**

**Exercice clos le 31 mars 2016** Exercice de 12 mois

A l'Associé Unique,

En exécution de la mission qui nous a été confiée par décision de l'associé unique, nous vous présentons notre rapport relatif à l'exercice clos le 31 mars 2016, sur :

- le contrôle des comptes annuels de la société LABORATOIRES NEGMA, tels qu'ils sont joints au présent rapport ;
- la justification de nos appréciations ;
- les vérifications et informations spécifiques prévues par la loi.

Les comptes annuels ont été arrêtés par le président. Il nous appartient, sur la base de notre audit, d'exprimer une opinion sur ces comptes.

**I. Opinion sur les comptes annuels**

Nous avons effectué notre audit selon les normes d'exercice professionnel applicables en France ; ces normes requièrent la mise en œuvre de diligences permettant d'obtenir l'assurance raisonnable que les comptes annuels ne comportent pas d'anomalies significatives. Un audit consiste à vérifier, par sondages ou au moyen d'autres méthodes de sélection, les éléments justifiant des montants et informations figurant dans les comptes annuels. Il consiste également à apprécier les principes comptables suivis, les estimations significatives retenues et la présentation d'ensemble des comptes. Nous estimons que les éléments que nous avons collectés sont suffisants et appropriés pour fonder notre opinion.

Nous certifions que les comptes annuels sont, au regard des règles et principes comptables français, réguliers et sincères et donnent une image fidèle du résultat des opérations de l'exercice écoulé ainsi que de la situation financière et du patrimoine de la société à la fin de cet exercice.

## II. Justification des appréciations

En application des dispositions de l'article L. 823-9 du Code de commerce relatives à la justification de nos appréciations, nous portons à votre connaissance les éléments suivants :

- L'actif immobilisé de la société comprend un fonds commercial d'une valeur brute de 21.617.270 euros et une valeur nette de 12.141.270 euros.
- Les règles et méthodes comptables présentent les modalités de suivi de la valeur de cet actif. La société a procédé sur l'exercice clos le 31 mars 2016 à un test de valeur de ce fonds commercial.

Nous avons vérifié la correcte application de ces méthodes et avons examiné les approches retenues pour déterminer la valeur d'inventaire de cet actif. Nous avons apprécié les données et les hypothèses sur lesquelles se fondent ces estimations, qui ont par nature un caractère incertain, et dont la réalisation est susceptible de différer parfois de façon significative des données prévisionnelles utilisées.

Les appréciations ainsi portées s'inscrivent dans le cadre de notre démarche d'audit des comptes annuels, pris dans leur ensemble, et ont donc contribué à la formation de notre opinion exprimée dans la première partie de ce rapport.

## III. Vérifications et informations spécifiques

Nous avons également procédé, conformément aux normes d'exercice professionnel applicables en France, aux vérifications spécifiques prévues par la loi.

Nous n'avons pas d'observation à formuler sur la sincérité et la concordance avec les comptes annuels des informations données dans le rapport de gestion du Président et dans les documents adressés à l'Associé Unique sur la situation financière et les comptes annuels.

Issy-Les-Moulineaux le 15 juin 2016

**Le Commissaire aux Comptes**



**CERA**  
**Daniel Buchoux**



2, rue Maurice Hartmann  
92 130 – Issy-Les-Moulineaux

**Laboratoires NEGMA S.A.S.U.**

Head office : 1 bis avenue Jean d'Alembert – 78 990 ELANCOURT

Share Capital : € 28.868.371

**Statutory auditors' report on the financial statements**

**For the year ended 31<sup>st</sup> March 2016** Exercise of 12 Month

At the single-shareholder,

In compliance with the assignment entrusted to us by your Shareholders' annual general meeting we hereby report to you, for the year ended 31st March 2016 on:

- the audit of the accompanying financial statements of the Company Laboratoires NEGMA ,
- the justification of our assessments
- the specific verifications and information required by law.

These financial statements have been approved by the Chairman. Our role is to express an opinion on these financial statements based on our audit.

**I. Opinion on the financial statements**

We conducted our audit in accordance with the professional standards applied in France. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the Company as at 31<sup>st</sup> March 2016 and of the results of its operations for the year then ended in accordance with French accounting principles.

## **II. Justification of our assessments**

In accordance with the requirements of article L.823-9 of the French Commercial Law (Code de commerce) relating to the justification of our assessments, we bring to your attention the following matters:

- The fixed assets contain a goodwill which gross amount is 21.617.270 euros and net amount about 12.141.270 euros.
- The fixed assets valuation methods present the conditions of the impairment test. The Company has proceeds an impairment test for the year ended 31st March 2016 of this goodwill.

We verify the right application of the valuation method and exam the approaches used to determinate the book value of this asset. We have appreciate the data used and the assumptions adopted as bases of this estimation.

These assessments were made in the context of our audit of the financial statements taken as a whole, and therefore contributed to the opinion we formed which is expressed in the first part of this report.

## **III. Specific verifications and information**

We also performed the specific verifications required by law.

We have no comments as to the fair presentation and the consistency with the financial statements of the information given in the management report of the Chairman, and in the documents addressed to the single-shareholder with respect to the financial position and the financial statements.

Issy-Les-Moulineaux June 15<sup>th</sup> 2016

**The statutory auditors**

**CERA**  
**Daniel Buchoux**



N° 11937\*03

①

**BALANCE SHEET - ASSETS**

D.G.I. N° 2050

Formulaire obligatoire (article 53A du Code général des impôts).

| Tax return filed in €                           |   | 31/03/2016                           |                             |                     | 31/03/2015         |                   |
|---|---|--------------------------------------|-----------------------------|---------------------|--------------------|-------------------|
|   |   | Gross amount                         | Amortization & depreciation | Net amount          | Net amount         |                   |
| Uncalled subscribed capital (1)                 |   | (I) AA                               |                             | 0,00                | 0                  |                   |
| FIXED ASSETS*                                   | INTANGIBLE ASSETS                                 | AB                                   | 0                           | AC 0                | 0                  |                   |
|   |   | Start-up costs*                      |                             |                     |                    |                   |
|   |   | CX                                   | 773 005                     | CQ 772 404          | 601                | 601               |
|   |   | Research & development costs*        |                             |                     |                    |                   |
|   |   | AF                                   | 533 562                     | AG 507 311          | 26 251             | 17 576            |
|   |   | Licences, patents and similar rights |                             |                     |                    |                   |
|   | AH  | 21 617 271                           | AI 9 476 000                | 12 141 271          | 12 501 271         |                   |
|   | Goodwill (1)                                      |                                      |                             |                     |                    |                   |
|   | AJ  | 0                                    | AK 0                        | 0                   | 0                  |                   |
|   | Other intangible assets                           |                                      |                             |                     |                    |                   |
|   | AL  | 0                                    | AM 0                        | 0                   | 0                  |                   |
|   | Cash advances & downpayments on intangible assets |                                      |                             |                     |                    |                   |
|   | AN  | 0                                    | AO 0                        | 0                   | 0                  |                   |
|   | TANGIBLE ASSETS                                   | Land                                 |                             |                     |                    |                   |
|   |   | AP                                   | 0                           | AQ 0                | 0                  | 0                 |
|   |   | Buildings                            |                             |                     |                    |                   |
|   |   | AR                                   | 32 140                      | AS 28 776           | 3 364              | 5 418             |
|   |   | Plant & equipment                    |                             |                     |                    |                   |
| AT  |   | 385 131                              | AU 231 243                  | 153 888             | 182 734            |                   |
| Other tangible assets                           |   |                                      |                             |                     |                    |                   |
| AV  | 1 580   | AW 0                                 | 1 580                       | 0                   |                    |                   |
| Assets under construction                       |   |                                      |                             |                     |                    |                   |
| AX  | 0   | AY 0                                 | 0                           | 0                   |                    |                   |
| Cash advances & downpayments on tangible assets |   |                                      |                             |                     |                    |                   |
| FINANCIAL ASSETS (2)                            | Shares held at equity value                       |                                      |                             |                     |                    |                   |
|   | CS  | 0                                    | CT 0                        | 0                   | 0                  |                   |
|   | Other shares                                      |                                      |                             |                     |                    |                   |
|   | CJ  | 252 456                              | CV 3 971                    | 248 485             | 248 485            |                   |
|   | Receivables related to investments                |                                      |                             |                     |                    |                   |
|   | BB  | 0                                    | BC 0                        | 0                   | 0                  |                   |
|   | Other capitalized securities                      |                                      |                             |                     |                    |                   |
| BD  | 0   | BE 0                                 | 0                           | 0                   |                    |                   |
| Loans   |   |                                      |                             |                     |                    |                   |
| BF  | 19 961 679  | BG 7 333 638                         | 12 628 041                  | 12 641 629          |                    |                   |
| Other financial assets*                         |   |                                      |                             |                     |                    |                   |
| BH  | 44 850  | BI 0                                 | 44 850                      | 44 454              |                    |                   |
| <b>TOTAL (II)</b>                               | <b>BJ</b>   | <b>43 601 673</b>                    | <b>BK 18 353 343</b>        | <b>25 248 330</b>   | <b>25 642 167</b>  |                   |
| CURRENT ASSETS                                  | INVENTORY*  | Raw materials & components           |                             |                     |                    |                   |
|   |   | BL                                   | 989 953                     | BM 2 906            | 987 047            | 1 494 167         |
|   |   | Work in progress (goods)             |                             |                     |                    |                   |
|   |   | BN                                   | 0                           | BO 0                | 0                  | 0                 |
|   |   | Work in progress (services)          |                             |                     |                    |                   |
|   | BP  | 0                                    | BQ 0                        | 0                   | 0                  |                   |
|   | Semi-finished & finished products                 |                                      |                             |                     |                    |                   |
|   | BR  | 907 800                              | BS 50 635                   | 857 165             | 1 004 377          |                   |
|   | Goods held for resale                             |                                      |                             |                     |                    |                   |
|   | BT  | 0                                    | BU 0                        | 0                   | 0                  |                   |
|   | RECEIVABLES                                       | Advances & downpayments to suppliers |                             |                     |                    |                   |
|   |   | BV                                   | 5 600                       | BW 0                | 5 600              | 272 466           |
| Trade receivables and related accounts * (3)    |   |                                      |                             |                     |                    |                   |
| BX  | 2 054 618   | BY 992 241                           | 1 062 377                   | 1 643 942           |                    |                   |
| Other receivables (3)                           |   |                                      |                             |                     |                    |                   |
| BZ  | 7 230 057   | CA 6 384 875                         | 845 183                     | 2 906 122           |                    |                   |
| Called subscribed capital, unpaid               |   |                                      |                             |                     |                    |                   |
| CB  | 0   | CC 0                                 | 0                           | 0                   |                    |                   |
| MISCELLANEOUS                                   | Investments (including own shares)                |                                      |                             |                     |                    |                   |
|   | CD  | 4 341 552                            | CE 24 206                   | 4 317 345           | 3 432 694          |                   |
| Bank balances                                   |   |                                      |                             |                     |                    |                   |
| CF  | 746 874   | CG 0                                 | 746 874                     | 2 773 677           |                    |                   |
| ADJUSTMENTS                                     | Prepayments* (3) (E)                              |                                      |                             |                     |                    |                   |
|   | CH  | 145 026                              | CI 0                        | 145 026             | 142 823            |                   |
|   | <b>GRAND TOTAL (III)</b>                          | <b>CJ</b>                            | <b>16 421 479</b>           | <b>CK 7 454 862</b> | <b>8 966 617</b>   | <b>13 670 266</b> |
|   | Expenses amortized over more than one year * (IV) |                                      |                             |                     |                    |                   |
|   | CW  | 0                                    |                             | 0                   | 0                  |                   |
| Premium on bond redemption (V)                  |   |                                      |                             |                     |                    |                   |
| CM  | 0   |                                      | 0                           | 0                   |                    |                   |
| Conversion differences - assets* (VI)           |   |                                      |                             |                     |                    |                   |
| CN  | 0   |                                      | 0                           | 0                   |                    |                   |
| <b>TOTAL (I à VI)</b>                           | <b>CO</b>   | <b>60 023 152</b>                    | <b>1A 25 808 205</b>        | <b>34 214 947</b>   | <b>39 312 434</b>  |                   |
| Foot notes: (1) Incl. lease agreements          |   |                                      | (2) Less than 12 months     | CP                  | (3) Over 12 months | CR                |
| Ownership reservations:                         |   | assets:                              | Inventory:                  | Receivables:        |                    |                   |



N° 11937\*03

Formulaire obligatoire (article 53A  
du Code général des impôts).

(2)

**BALANCE SHEET - LIABILITIES before distribution**

D.G.I. N° 2051

| Company name : LABORATOIRES NEGMA                                   |   |                                    | 31/03/2016        | 31/03/2015        |                   |
|---|---|------------------------------------|-------------------|-------------------|-------------------|
| EQUITY  | Share capital (1)* (included paid up )  | 28 868 371 )                       | DA                | 28 868 371        | 28 868 371        |
|   | Share, fusion, .... premiums  |                                    | DB                | 0                 | 0                 |
|   | Acquisition differential (2)* (including equity differential                  | EK )                               | DC                | 0                 | 0                 |
|   | Legal reserve (3)   |                                    | DD                | 2 886 837         | 2 615 813         |
|   | Statutory & contractual reserves  |                                    | DE                | 0                 | 0                 |
|   | Regulatory reserves (3)* (incl. foreign currency translation reserve)         | B1 )                               | DF                | 0                 | 0                 |
|   | Other reserves (incl. reserve on purchase of works of art from live artists)* | EJ )                               | DG                | 0                 | 0                 |
|   | Retained earnings / losses  |                                    | DH                | 112 665           | -4 009 492        |
|   | Net income or loss  |                                    | DI                | 698 060           | 6 392 650         |
|   | Investment subsidies  |                                    | DJ                | 0                 | 0                 |
|   | Regulatory provisions*  |                                    | DK                | 0                 | 0                 |
|   |   | <b>TOTAL (I)</b>                   | DL                | <b>32 565 933</b> | <b>33 867 343</b> |
| OTHER EQUITY  | Proceeds from issue of equity securities                                      |                                    | DM                | 0                 | 0                 |
|   | Conditional advances  |                                    | DN                | 0                 | 0                 |
|   | <b>TOTAL (II)</b>   | DO                                 | <b>0</b>          | <b>0</b>          |                   |
| PROVISIONS  | Short-term provisions   |                                    | DP                | 4 300             | 1 965 975         |
|   | Long-term provisions  |                                    | DQ                | 71 500            | 65 819            |
|   | <b>TOTAL (III)</b>  | DR                                 | <b>75 800</b>     | <b>2 031 794</b>  |                   |
| PAYABLES(4)   | Convertible bond loans  |                                    | DS                | 0                 | 0                 |
|   | Other bond loans  |                                    | DT                | 0                 | 0                 |
|   | Borrowings from financial institutions (5)                                    |                                    | DU                | 1 461             | 1 727             |
|   | Borrowings from other sources (including borrowings secured by shares)        | EI )                               | DV                | 0                 | 0                 |
|   | Advances and downpayments collected on orders                                 |                                    | DW                | 0                 | 0                 |
|   | Trade payables and related accounts   |                                    | DX                | 861 013           | 1 980 369         |
|   | Tax payable, payroll and social contributions                                 |                                    | DY                | 577 436           | 710 132           |
|   | Payables on fixed assets and related accounts                                 |                                    | DZ                | 0                 | 0                 |
|   | Other payables  |                                    | EA                | 133 304           | 721 068           |
| ADJUST. Deferred income(4)  |   | EB                                 | 0                 | 0                 |                   |
|   | <b>TOTAL (IV)</b>   | EC                                 | <b>1 573 213</b>  | <b>3 413 296</b>  |                   |
|   | Conversion differences - liabilities * (V)                                    | ED                                 | 0                 | 0                 |                   |
|   | <b>GRAND TOTAL (I à V)</b>  | EE                                 | <b>34 214 947</b> | <b>39 312 434</b> |                   |
| FOOTNOTES   | (1) Acquisition differential included in share capital                        |                                    | EB                |                   |                   |
|   | (2) { including   | Special Revaluation reserve (1959) | EC                |                   |                   |
|   |   | Non obligatory revaluation reserve | ED                |                   |                   |
|   |   | Revaluation reserve (1976)         | EE                |                   |                   |
|   | (3) Including long-term capital gains regulatory reserve *                    |                                    | EF                |                   |                   |
| (4) Payables and deferred income under 12 months                    |   | EG                                 | 1 571 752         | 3 413 296         |                   |
| (5) including loans repayable on demand and overdrawn bank accounts |   | EH                                 | 1 461             | 1 727             |                   |



N° 10167\*05

Formulaire obligatoire (article 53A du Code général des impôts)

③

**PROFIT & LOSS ACCOUNT**

D.G.I. N° 2052

| Company name : LABORATOIRES NEGMA                        |  |                                  |                  |              |                  |                   |        |  |
|--|--|----------------------------------|------------------|--------------|------------------|-------------------|--------|--|
|  |  | 31/03/2016                       |                  |              | 31/03/2015       |                   |        |  |
|  |  | Domestic                         | export           | Total        |                  |                   |        |  |
| REVENUE FROM OPERATIONS                                  | Sales of goods held for resale*                                    | FA -571                          | FB 0             | FC -571      | 1 935 686        |                   |        |  |
|  | Sale of finished goods*<br>services*                               | FD 7 420 519                     | FE 202 063       | FF 7 622 582 | 15 914 101       |                   |        |  |
|  |  | FG 344 366                       | FH 0             | FI 344 366   | 432 785          |                   |        |  |
|  | Net sales*   | FJ 7 764 314                     | FK 202 063       | FL 7 966 377 | 18 282 572       |                   |        |  |
|  | Stored production*   |                                  |                  |              | FM -96 581       | -501 929          |        |  |
|  | Capitalized production*  |                                  |                  |              | FN 0             | 0                 |        |  |
|  | Operating subsidies  |                                  |                  |              | FO 12 580        | 2 100             |        |  |
|  | Amortization & depreciation provisions reversal* (9)               |                                  |                  |              | FP 207 711       | 374 322           |        |  |
|  | Other proceeds (1) (11)  |                                  |                  |              | FQ 0             | 0                 |        |  |
|  | <b>TOTAL OPERATING GAINS (2) (I)</b>                               |                                  |                  |              | FR 8 090 088     | <b>18 157 064</b> |        |  |
| OPERATING EXPENSES                                       | Purchase of goods held for resale (including customs duties) *     |                                  |                  |              | FS 0             | 522 679           |        |  |
|  | Changes in inventory (goods held for resale)                       |                                  |                  |              | FT 0             | 481 575           |        |  |
|  | Purchase of raw materials and components (including excise duty) * |                                  |                  |              | FU 1 825 204     | 2 556 892         |        |  |
|  | Changes in inventory (raw materials and components)*               |                                  |                  |              | FV 505 428       | 801 115           |        |  |
|  | Other external purchases (3) (6bis)*                               |                                  |                  |              | FW 3 002 928     | 4 171 807         |        |  |
|  | Taxes, contributions and related costs*                            |                                  |                  |              | FX 162 028       | 516 812           |        |  |
|  | Payroll costs*   |                                  |                  |              | FY 766 584       | 791 808           |        |  |
|  | Social contributions (10)  |                                  |                  |              | FZ 381 704       | 363 174           |        |  |
|  | OPERATING PROVISIONS   | - on fixed assets :              | - amortization*  |              | GA 38 803        | 165 039           |        |  |
|  |  |                                  | - depreciation * |              | GB 0             | 0                 |        |  |
|  |  | - on current assets : provisions |                  |              |                  | GC 71 346         | 25 200 |  |
|  |  | - contingencies : provisions     |                  |              |                  | GD 12 736         | 25 792 |  |
|  | Other costs (12)   |                                  |                  |              | GE 572 540       | 511 369           |        |  |
|  | <b>TOTAL OPERATING EXPENSES (4) (II)</b>                           |                                  |                  |              | GF 7 339 300     | <b>10 933 263</b> |        |  |
| <b>1 - OPERATING INCOME (I - II)</b>                     |  |                                  |                  | GG 750 787   | <b>7 223 802</b> |                   |        |  |
| COMMON TRANSACTIONS                                      | Attributed income or transferred loss *                            |                                  |                  |              | GH 0             | 0                 |        |  |
|  | Loss assumed or transferred income *                               |                                  |                  |              | GI 0             | 0                 |        |  |
| FINANCIAL GAINS  | Financial income from investments (5)                              |                                  |                  |              | GJ 1 888         | 2 381             |        |  |
|  | Income from other investment securities (5)                        |                                  |                  |              | GK 73 713        | 115 101           |        |  |
|  | Other interest and related income (5)                              |                                  |                  |              | GL 23 637        | 9 843             |        |  |
|  | Accrual reversal and transfer charges                              |                                  |                  |              | GM 930 428       | 265 062           |        |  |
|  | Profits on exchange rates  |                                  |                  |              | GN 0             | 153               |        |  |
|  | Net gains on sales of investment securities                        |                                  |                  |              | GO 13 274        | 20 790            |        |  |
| <b>TOTAL FINANCIAL GAINS (V)</b>                         |  |                                  |                  | GP 1 042 940 | <b>413 330</b>   |                   |        |  |
| FINANCIAL COSTS  | Provisions for financial amortization and depreciation *           |                                  |                  |              | GQ 456 927       | 315 690           |        |  |
|  | Interests and related expenses (6)                                 |                                  |                  |              | GR 0             | 0                 |        |  |
|  | Losses on exchange rates   |                                  |                  |              | GS 226           | 593               |        |  |
|  | Net loss on sales of investment securities                         |                                  |                  |              | GT 4 269         | 1 991             |        |  |
| <b>TOTAL FINANCIAL COSTS (VI)</b>                        |  |                                  |                  | GU 461 422   | <b>318 273</b>   |                   |        |  |
| <b>2 - FINANCIAL RESULT (V - VI)</b>                     |  |                                  |                  | GV 581 517   | <b>95 056</b>    |                   |        |  |
| <b>3 - OPERATING PROFIT BEFORE TAX (I-II-IV +V - VI)</b> |  |                                  |                  | GW 1 332 305 | <b>7 318 858</b> |                   |        |  |



N° 10947\*03

④

**PROFIT AND LOSS ACCOUNT (continued)**

D.G.I. N° 2053

Formulaire obligatoire (article 53A  
du Code général des impôts).

|   |   | Company name : LABORATOIRES NEGMA |                   |                   |
|---|---|-----------------------------------|-------------------|-------------------|
|   |   | 31/03/16                          | 31/03/2015        |                   |
| EXCEPTIONAL GAINS   | Exceptional operating gains   | HA                                | 331 026           | 362 186           |
|   | Exceptional capital gains *   | HB                                | 292               | 2 860             |
|   | Accrual reversal and transfer charges                                   | HC                                | 1 961 675         | 520 815           |
|   | <b>TOTAL EXCEPTIONAL GAINS (7) (VII)</b>                                | <b>HD</b>                         | <b>2 292 994</b>  | <b>885 861</b>    |
| EXCEPTIONAL LOSSES  | Exceptional operating losses (6bis)                                     | HE                                | 2 088 098         | 537 657           |
|   | Exceptional capital losses *  | HF                                | 284               | 3                 |
|   | Exceptional amortization and depreciation                               | HG                                | 360 000           | 195 760           |
|   | <b>TOTAL EXCEPTIONAL LOSSES (7) (VIII)</b>                              | <b>HH</b>                         | <b>2 448 381</b>  | <b>733 420</b>    |
| <b>4 - EXCEPTIONAL INCOME OR LOSS (VII - VIII)</b>        |   | <b>HI</b>                         | <b>-155 387</b>   | <b>152 441</b>    |
| Employee profit sharing scheme                            |   | HJ                                | 0                 | 0                 |
| Corporate tax *   |   | HK                                | 478 858           | 1 078 649         |
| <b>TOTAL INCOME (I+III+V+VII)</b>                         |   | <b>HL</b>                         | <b>11 426 021</b> | <b>19 456 255</b> |
| <b>TOTAL EXPENSES (II+IV+VI+VIII+IX+X)</b>                |   | <b>HM</b>                         | <b>10 727 961</b> | <b>13 063 605</b> |
| <b>5 - Profit or loss (Total income - total expenses)</b> |   | <b>HN</b>                         | <b>698 059,75</b> | <b>6 392 650</b>  |
| FOOTNOTES   | (1) including net partial gains on long-term capital gains              | HO                                |                   |                   |
|   | (2) real-estate rent  | HY                                |                   | 7 526             |
|   | operating gains related to prior years (break-up required in (8) below) | IG                                | 183 916           | 4 507             |
|   | (3) - equipment on lease *  | HP                                |                   |                   |
|   | - buildings on lease  | HQ                                |                   |                   |
|   | (4) incl. operating losses related to prior years (8)                   | IH                                | 292 043           | 14 763            |
|   | (5) incl. Income from related parties                                   | IJ                                | 73 713            | 115 101           |
|   | (6) incl. interests from related parties                                | IK                                |                   |                   |
|   | (6bis) incl. Donations to charitable causes (art. 238 bis du C.G.I.)    | HX                                | 1 447             |                   |
|   | (9) incl. Transfer charges  | A1                                |                   |                   |
|   | (10) incl. Personal contributions of the manager (13)                   | A2                                |                   |                   |
|   | (11) incl. Royalties on licences and patents (proceeds)                 | A3                                |                   |                   |
|   | (12) incl. Royalties on licences and patents (expenses)                 | A4                                | 504 944           | 511 292           |
| (13) incl. non compulsory additional contributions        | A6  |                                   |                   |                   |
|   | compulsory  | A9                                |                   |                   |
| (7) Break-up of exceptional gains & loss                  |   | Current year                      |                   |                   |
|   |   | Exceptional loss                  | Exceptional gain  |                   |
| Please refer to following appendix for details            |   |                                   |                   |                   |
|   |   |                                   |                   |                   |
| (8) Break-up of gains and losses related to prio years :  |   | Current year                      |                   |                   |
|   |   | Prior year losses                 | Prior year gains  |                   |
| Please refer to following appendix for details            |   |                                   |                   |                   |
|   |   |                                   |                   |                   |
|   |   |                                   |                   |                   |



## BREAK-UP OF EXCEPTIONAL GAINS AND LOSSES

Entity name: SAS LABORATOIRES NEGMA

Fiscal year ending: 31<sup>st</sup> March 2016

| DETAILS   | Amount              |                |                      |
|---|---------------------|----------------|----------------------|
|   | Operating           | Financial      | Exceptional          |
| <b>EXCEPTIONAL GAINS</b>                        |                     |                |                      |
| <b>EXCEPTIONAL GAINS ON OPERATIONS</b>          | <b>-331 025,00</b>  |                |                      |
| Miscellaneous gains on suppliers                | -4 493,00           |                |                      |
| Compensation from Dr Uge                        | -25 200,00          |                |                      |
| Compensation from prior employee                | -838,00             |                |                      |
| Gains on Alkochym settlement agreement          | -120 236,00         |                |                      |
| Outstanding Aelslife invoices written off       | -177 191,00         |                |                      |
| Compensation from Synteco                       | -3 000,00           |                |                      |
| Refund on out of date lunch vouchers            | -67,00              |                |                      |
| <b>EXCEPTIONAL GAINS ON ASSETS</b>              |                     | <b>-291,00</b> |                      |
| Sale of fixed assets                            |                     | -291,00        |                      |
| <b>ACCRUAL REVERSALS &amp; TRANSFER CHARGES</b> |                     |                | <b>-1 961 674,00</b> |
| Reversal of redundancy accrual                  |                     |                | -230 297,00          |
| Reversal of Alkopharm accrual                   |                     |                | -1 731 377,00        |
| <b>EXCEPTIONAL LOSSES</b>                       |                     |                |                      |
| <b>EXCEPTIONAL LOSSES ON OPERATIONS</b>         | <b>2 088 095,00</b> |                |                      |
| Settlement agreement with ex-employee           | 119 598,00          |                |                      |
| Alkopharm disputed invoices                     | 1 958 097,00        |                |                      |
| Adjustement on social contributions             | 4 151,00            |                |                      |
| Miscellaneous payment differences               | 4 349,00            |                |                      |
| Donations                                       | 1 447,00            |                |                      |
| Penalties                                       | 453,00              |                |                      |
| <b>EXCEPTIONAL LOSSES ON ASSETS</b>             |                     | <b>283,00</b>  |                      |
| Net value of fixed assets sold                  |                     | 283,00         |                      |
| <b>EXCEPTIONAL DEPRECIATION ACCRUAL</b>         |                     |                | <b>360 000,00</b>    |
| Goodwill depreciation                           |                     |                | 360 000,00           |
| <b>GRAND TOTAL</b>                              | <b>1 757 070,00</b> | <b>-8,00</b>   | <b>-1 601 674,00</b> |

**BREAK-UP OF GAINS AND LOSSES RELATED TO PRIOR YEAR**

Entity name: SAS LABORATOIRES NEGMA

Fiscal year ending: 31<sup>st</sup> March 2016

| DETAILS                             | Amount           |               |                    |
|-------------------------------------|------------------|---------------|--------------------|
|                                     | Operating        | Financial     | Exceptional        |
| <b>LOSSES RELATED TO PRIOR YEAR</b> | <b>21 622,00</b> | <b>0,00</b>   | <b>270 420,00</b>  |
| Fuel                                | 180,00           |               |                    |
| Service charges                     | 7 656,00         |               |                    |
| Car maintenance                     | 13,00            |               |                    |
| Insurance                           | -2 500,00        |               |                    |
| Commissions                         | 186,00           |               |                    |
| Advertising                         | 999,00           |               |                    |
| Haulage                             | 9 156,00         |               |                    |
| Stamps                              | 7,00             |               |                    |
| Bank charges                        | 923,00           |               |                    |
| Miscellaneous services              | 3 450,00         |               |                    |
| Membership fees                     | 1 405,00         |               |                    |
| Training                            | 1 667,00         |               |                    |
| Poll tax                            | 5 965,00         |               |                    |
| Waste tax                           | -7 485,00        |               |                    |
| Exceptional charges on operations   |                  |               | 270 420,00         |
| <b>LOSSES RELATED TO PRIOR YEAR</b> | <b>-6 639,00</b> | <b>-85,00</b> | <b>-177 191,00</b> |
| Training grant                      | -2 605,00        |               |                    |
| Discounts and rebates               | -4 034,00        |               |                    |
| Interests on current account        |                  | -85,00        |                    |
| Exceptional gains on operations     |                  |               | -177 191,00        |
| <b>GRAND TOTAL</b>                  | <b>14 983,00</b> | <b>-85,00</b> | <b>93 229,00</b>   |